'BioBusiness Network delivered on all counts: a senior audience, informative presentations and an informal atmosphere for successful partnering'
Paul Higham, Director of Commercial Development, Ark Therapeutics

In September 2008, leading biotech CEOs and top pharma representatives met to network, discuss industry change and do the deals which will ensure success in 2009. With presentations from Wyeth, Novartis, Roche, Pfizer, Lilly, Boehringer, AstraZeneca, Merck, GSK and many others, delegates got true insight into the deals which have shaped 2008.

Once again, BioBusiness Network proved essential to delegates as a forum for personal and informal networking. No other conference offers the same high level of seniority and intimacy as BioBusiness Network, resulting in delegates having the time and the opportunity to meet with their partners of choice in a relaxed and unhurried setting. For your chance to meet with the industry’s most powerful decision makers, make sure you sign up for BioBusiness 2009!

Key speakers at BioBusiness Network 2008:

• Jose Carlos Gutierrez-Ramos,SVP and Head of Immuno-Inflammation CEDD, GlaxoSmithKline
  
• Joern-Peter Halle, Head of Early Stage Licensing, Merck Serono
  
• Joe Messina,Senior Business Development Director, Wyeth Pharmaceuticals
  
• James Williams, Director, Business Development, Roche
  
• Knut Sturmhoefel, Alliance Management, Novartis
  
• Anke Friese, CD Licensing, Boehringer Ingelheim
  
• Jeremy Carmichael, Director of Business Development, Astex
  
• Onno van de Stolpe, CEO, Galapogos
  
• Elias Papatheodorou, CEO, Novosom
  
• Morten Faester, Senior Director Business Development, Nycomed
  
• Denise Good, Executive Director, Business Development, AstraZeneca
  
• Ruth Keir, Executive Director, Business Development, Pfizer
  
• Sarah Clements, Senior Legal Council, Novartis
  
• Tony Chen, Partner, Jones Day
  
• Darren Ji, CEO, PharmaLegacy
  
• Gary Deeb, VP Business Development, Glenmark Pharma
  
• Tarmo Kivi, CEO, Celcure Biotech
  
• Andrew Wood, Executive Director Global External Research, Eli Lilly
  
• Sarah Garner, Associate Director, Research & Development, NICE
  
• Dr Simon Best, Chairman, Ardana
  
• Dr Frank Morich, CEO, Noxxon
  
• Michael Hunt, CEO, Reneuron

Highlights of BioBusiness Network included:

• Groundbreaking deal case studies, including GSK/Regulus and Merck Serono/Archemix which gave delegates the chance to put their questions to the speakers and uncover the details of the deals
  
• The Oligoneucleotides panel, which brought together some of the industry’s most exciting players to discuss the future of the field
  
• Headline panel discussions on big pharma strategy and VC investment, giving delegates the chance to gain competitive insight into upcoming market trends
  
• Exclusive insight from Sarah Garner of NICE, who shared the latest guidelines from the institute as well as putting them into a global context. Delegates then benefited from the chance to speak to Sarah in an informal context and put their questions to her directly.
  
• A full day dedicated to partnering skills, with information on due diligence, valuation, deal processes and alliance management from senior pharma and biotech speakers

Speaking Opportunities

If you are interested in Speaking at BioBusiness Network 2009 please contact Herve Bavazzano at herve.bavazzano@wbr.co.uk or call on+44 207 368 9400

CD ROM

To purchase the BioBusiness Network CD ROM (all presentations included), contact us on +44 (0) 20 7368 9400

Sponsorship Opportunities

To learn more about sponsorship opportunities at BioBusiness 2009 please contact Herve Bavazzano at WBR on +44 (0) 207 368 9400 or email herve.bavazzano@wbr.co.uk